AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 OCT 17 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Researchers at Scripps Clinic and Research Institute in California have used a cytokine fusion protein to heighten the effectiveness of oral DNA vaccine against murine tumors.
Combination therapy, in effect, makes a good vaccine better. A.G. Niethammer and colleagues used a mouse-human antiganglioside GD2-interleukin (IL)-2 fusion protein (ch14, 18-IL2) to show that targeting IL-2 at the tumor microenvironment boosted immune response against murine melanoma when mice were administered oral DNA vaccines produced by fusing murine ubiquitin genes with murine melanoma peptide epitopes. Attenuated Salmonella typhimurium was used as the DNA vector.
"This combination therapy led to the complete rejection of a lethal challenge with B78D14 murine melanoma cells in six of eight mice and a marked suppression of subcutaneous tumor growth in the two remaining animals," described Niethammer and associates.
Both CD8[superscript]+ and CD4[superscript]+ T cells were activated following vaccination, according to researchers. They noted a cascade of events, including tumor necrosis factor (TNA)-alpha and interferon (IFN)-gamma secretion, ultimately leading to the ...
Source: HighBeam Research, Interleukin-2 Fusion Protein Enhances DNA Vaccine Effectiveness.(DNA...